• TAI-1 Hec1 Inhibitor: Assays and Workflows

  2026-08-25

  TAI-1 provides a practical way to connect Hec1–Nek2 disruption with mitotic failure, cancer cell proliferation inhibition, and apoptotic cell death induction. This guide presents dose-response, imaging, combination-treatment, and RB1-aware workflows for triple negative breast cancer research, liver cancer research, and organoid-based studies.

• MLN4924 HCl salt: Practical Assay Workflows

  2026-08-25

  MLN4924 HCl salt enables time-resolved interrogation of NAE-dependent neddylation, cullin-RING ligase activity, protein turnover, and cell-cycle phenotypes. This workflow-focused guide also shows how the compound can extend viral immunity studies by testing whether SCF-dependent RIPK3 degradation requires an intact neddylation pathway.

• KN-62: A Causal Lens on Calcium-Signaling Assays

  2026-08-24

  KN-62 is a selective CaMKII inhibitor that can help researchers separate calcium-dependent signaling from downstream synaptic and cellular outcomes. This article develops an assay-centered framework linking KN-62 mechanism, secretase-dependent Neuroligin 1 signaling, and rigorous interpretation of calcium pathway experiments.

• 10058-F4: c-Myc-Max Inhibition Workflows

  2026-08-24

  10058-F4 enables time-resolved studies of c-Myc/Max-dependent transcription, mitochondrial apoptosis, leukemia differentiation, and TERT regulation. This practical guide connects assay design with recent stem-cell chromatin findings while emphasizing formulation, controls, and model-specific troubleshooting.

• 10058-F4 c-Myc-Max Dimerization Inhibitor Guide

  2026-08-23

  10058-F4 turns c-Myc/Max disruption into a practical workflow spanning transcriptional assays, apoptosis profiling, acute myeloid leukemia research, and prostate cancer models. This guide pairs product-handling guidance with evidence-aware strategies for connecting c-Myc biology to emerging APEX2–TERT questions without overstating the data.

• Testosterone Bounce and Prognosis After Degarelix

  2026-08-22

  A 2024 retrospective study found that a testosterone bounce, defined by recovery from a nadir below 20 ng/dL to a subsequent maximum of at least 20 ng/dL, was associated with better overall and cancer-specific survival in prostate cancer patients receiving degarelix. The finding suggests that serial testosterone kinetics may complement PSA-based assessment, although prospective validation and assay standardization are still needed.

• 10058-F4: Practical c-Myc-Max Inhibition Workflows

  2026-08-22

  Use 10058-F4 to connect c-Myc:MAX disruption with apoptosis, leukemia differentiation, and TERT regulation in human pluripotent stem cells. This workflow-focused guide covers compound handling, assay design, mechanistic controls, and troubleshooting for cell-based and translational studies.

• Cyclopamine Workflow for Hedgehog Cancer Studies

  2026-08-21

  Cyclopamine is a practical Hedgehog signaling inhibitor for connecting Smoothened blockade with proliferation, apoptosis, and developmental phenotypes. This workflow emphasizes dose design, pathway-specific controls, orthogonal readouts, and careful interpretation when extending cancer assays toward epigenetic or neuroinflammatory research.

• Cytarabine and Cell Death: From DNA Damage to Translation

  2026-08-20

  Cytarabine (AraC) is more than a conventional nucleoside analog DNA synthesis inhibitor: it is a translational probe for linking deoxycytidine kinase activation, replication stress, p53 signaling, and apoptosis. This article shows how that framework can be extended—carefully and without overclaiming—to research on virus-regulated necroptosis and RIPK3 degradation.

• WM-8014: A Time-Gated KAT6A Strategy

  2026-08-20

  WM-8014 is a potent KAT6A inhibitor for connecting reversible acetyl-CoA-site inhibition with senescence, cell-cycle arrest, and resistance biology. This article explains how time-gated screening logic can improve assay design and interpretation in cancer biology research.

• PF-573228: Practical FAK Inhibitor Workflows

  2026-08-19

  PF-573228 is a potent FAK inhibitor for separating matrix-mechanical signals from downstream cell behavior. This guide translates the LAMB1–FAK–MEK1/2 dentinogenesis finding into actionable workflows for mineralization, cancer migration, and endothelial assays, with practical controls for target engagement and toxicity.

• WZ4003: Translational Precision in NUAK Signaling

  2026-08-19

  WZ4003 offers a mechanistically anchored way to interrogate NUAK1/2 signaling across cancer biology and neurodegenerative disease research. This thought-leadership perspective connects target engagement, migration and cell-cycle phenotypes, and tau Ser356 biology with practical guidance for translational assay design.

• IPR-803: Urokinase Receptor Inhibitor Workflows

  2026-08-18

  IPR-803 is a mechanistic tool for separating uPAR–uPA-driven tumor invasion from general cytotoxicity. This guide covers biochemical validation, breast and pancreatic cancer workflows, assay controls, formulation considerations, and troubleshooting for reproducible translational studies.

• 3-Hydroxybutyrate (BHBA): Assay Design

  2026-08-18

  3-Hydroxybutyrate (BHBA) is more than a ketone fuel: it connects fatty acid oxidation, ferroptosis control, membrane biology, and chromatin regulation. This guide translates recent stroke research into practical assay-design decisions for metabolic and epigenetic studies.

• Cell Senescence β-Galactosidase Staining Kit Workflow

  2026-08-17

  Build a practical senescent cell detection workflow around SA-β-Gal activity, from model validation to senolytic drug screening. This guide combines X-gal staining, imaging controls, orthogonal viability measurements, and troubleshooting strategies for more reproducible cell aging research.

7960 records 1/531 page Next 12345 下5页 Last page